AbbVie (NYSE: ABBV) revenue
AbbVie reported revenue of $61,160m for fiscal 2025, 8.6% more than in fiscal 2024 ($56,334m). Since fiscal 2016 its revenue has grown by 138.6%, an average growth of 10.1% a year.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $61,160m | +8.6% | $15,075m | 24.6% |
| 2024 | $56,334m | +3.7% | $9,137m | 16.2% |
| 2023 | $54,318m | −6.4% | $12,757m | 23.5% |
| 2022 | $58,054m | +3.3% | $18,117m | 31.2% |
| 2021 | $56,197m | +22.7% | $17,924m | 31.9% |
| 2020 | $45,804m | +37.7% | $11,363m | 24.8% |
| 2019 | $33,266m | +1.6% | $12,983m | 39.0% |
| 2018 | $32,753m | +16.1% | $6,383m | 19.5% |
| 2017 | $28,216m | +10.1% | $9,545m | 33.8% |
| 2016 | $25,638m | — | $9,340m | 36.4% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Questions about the revenue of AbbVie
- How much revenue did AbbVie make in fiscal 2025?
- AbbVie reported revenue of $61,160m for fiscal 2025, compared with $56,334m in fiscal 2024.
- How much has the revenue of AbbVie grown?
- Between fiscal 2016 and fiscal 2025 it went from $25,638m to $61,160m: 138.6% more, an average growth of 10.1% a year.
- What was the best year for revenue at AbbVie?
- Of its last 10 fiscal years, fiscal 2025, with $61,160m.
- Where do the figures for AbbVie come from?
- From the annual report (Form 10-K) that AbbVie files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that AbbVie files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on AbbVie: the AbbVie page · annual accounts · net income · dividends paid · insider transactions.
Dividend per share of AbbVie by fiscal year, with the filing behind every figure: AbbVie dividend history.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.